- Home
- FCAP vs GALT Comparison
FCAP vs GALT Comparison
Compare FCAP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | GALT |
|---|---|---|
| Founded | 1891 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.1M | 199.2M |
| IPO Year | 1998 | 2008 |
Fundamental Metrics
Financial Performance| Metric | FCAP | GALT |
|---|---|---|
| Price | $55.26 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 1.9K | ★ 297.5K |
| Earning Date | 04-24-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 36.97 | 36.84 |
| EPS | ★ 4.89 | N/A |
| Revenue | ★ $7,170,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.08 | ★ N/A |
| Revenue Growth | ★ 1.57 | N/A |
| 52 Week Low | $33.88 | $1.22 |
| 52 Week High | $71.00 | $7.13 |
Technical Indicators
Market Signals| Indicator | FCAP | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 42.14 |
| Support Level | $50.24 | $2.18 |
| Resistance Level | $56.40 | $2.60 |
| Average True Range (ATR) | 0.89 | 0.14 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 79.57 | 23.42 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.